aprotinin
Sign in to saveAlso known as BAYER-A-128, RP-9921, BPTI, bovine pancreatic trypsin inhibitor, Riker 52G, trypsin Inhibitor
The drug aprotinin (AP, Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is a small protein bovine pancreatic trypsin inhibitor (BPTI), or basic trypsin inhibitor of bovine pancreas, which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decr
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 477350259
- Drug.IUPAC_name
- Aprotinin
- Drug.image
- Aprotinin.png
- Drug.width
- 181
- Drug.pregnancy_category
- X
- Drug.legal_UK
- POM
- Drug.legal_status
- Rx-only
- Drug.dependency_liability
- None
- Drug.routes_of_administration
- Intravenous
- Drug.bioavailability
- 100% (intravenous)
- Drug.CAS_number
- 9087-70-1
- Drug.ATC_prefix
- B02
- Drug.ATC_suffix
- AB01
- Drug.DrugBank
- DB06692
- Drug.UNII
- 04XPW8C0FL
- Drug.KEGG
- D02971
- Drug.ChemSpiderID
- none
via Wikipedia infobox
Research
8,404 papers- Aprotinin.The Annals of pharmacotherapy · 1996
- Aprotinin.International anesthesiology clinics · 2004
- Aprotinin in perspective.The Annals of thoracic surgery · 1993
- Aprotinin in cardiac surgery.Expert review of cardiovascular therapy · 2006
- Aprotinin therapy.British journal of anaesthesia · 1994
via PubMed
~11 min read
Encyclopedic overview
9 sectionsContents
- Chemistry
- Mechanism of drug action
- Drug efficacy
- Drug safety
- In vitro use
- History
- Current findings
- References
- External links
The drug aprotinin (AP, Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is a small protein bovine pancreatic trypsin inhibitor (BPTI), or basic trypsin inhibitor of bovine pancreas, which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes. Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies. Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted. Nordic became distributor of aprotinin in 2012.
==Chemistry==
Excerpted from Wikipedia’s “aprotinin” article, available under the CC BY-SA 4.0 licence.